Chinese Regulators OK $43B Medtronic-Covidien Inversion
Medtronic Inc. and Covidien PLC inched closer to completing their $42.9 billion tax-inversion deal on Thursday with approval from Chinese regulators, wrapping up the controversial transaction's antitrust review and turning the...To view the full article, register now.
Already a subscriber? Click here to view full article